Bristol Serzone discussions with Health Canada
Bristol has entered discussions with Canadian regulators over the risk/benefit profile and marketing status of its antidepressant Serzone, the company says. Serzone (nefazodone) has been associated with reports of hepatic failure; the company added a "black box" warning to labeling for the antidepressant in 2001 following 18 reports of liver failure, including 13 deaths (1"The Pink Sheet" Dec. 10, 2001, p. 22). Bristol withdrew Serzone from the market in Europe earlier this year (2"The Pink Sheet" Jan. 13, 2003, p. 23)...
You may also be interested in...
FDA is comfortable with Serzone's current labeling, the agency said following Bristol-Myers Squibb's decision to pull the antidepressant off the market in Europe
Additional warnings for Bristol-Myers Squibb's antidepressant Serzone (nefazodone) suggest, but do not require, liver monitoring
The developers of eleven new drugs could learn this week whether the European Medicines Agency will set them on course for pan-EU marketing approval.